Table 2.
Positive predictive value and sample collection timing of low-positive versus clear-positive anti-MOG results reported out from London Health Sciences Centre Clinical Immunology laboratory.
| All positive anti-MOG results N = 85 | Low-positive anti-MOG results (Titer < 1:100) N = 47 | Clear-positive anti-MOG results (Titer ≥ 100) N = 38 | p-value* | |
|---|---|---|---|---|
| PPV (overall) | 82% | 72% | 95% | 0.009 |
| PPV (pediatric) | 91% | 89% | 92% | >0.99 |
| PPV (adult) | 68% | 47% | 100% | 0.004 |
| Proportion of TP who received immunotherapy prior to sample collection | 69% | 88% | 50% | 0.0007 |
| Median time from symptom onset to TP sample collection, days (range) | 101.5 (1–2,793) | 849 (7–2,793) | 17 (1–2,405) | <0.00001 |
*p-value refers to comparison of difference between low-positive and clear-positive anti-MOG results.
MOG, myelin oligodendrocyte glycoprotein; PPV, positive predictive value; TP, true-positive.
Bolded values represent statistically significant results.